Advertisement

The Role of the Renin-Angiotensin System in Erectile Dysfunction: Present and Future

  • Rodrigo Araujo Fraga-SilvaEmail author
  • Nikolaos Stergiopulos
Chapter

Abstract

The renin-angiotensin system (RAS) is a key regulator of the cardiovascular system. Furthermore, clear compelling evidence indicates that this system is an essential modulator of penile erectile. Higher levels of angiotensin (Ang) II, the main component of RAS, are found in the corpus cavernosum when compared to the systemic circulation. Moreover, emerging findings indicate increased activity between Ang II and the Ang type 1 (AT1) receptor, possibly contributing to the development of erectile dysfunction (ED). Alternatively, angiotensin-converting enzyme inhibitors (ACEi) and Ang receptor blockers (ARBs) demonstrated protective effects on erection. In the last decade, parallel pathways within RAS have been described, expanding our current understanding of this system and opening novel opportunities. Contrary to Ang II, the Ang-(1–7) peptide produces cardiovascular-protective responses through the activation of Mas receptor. Within the corpus cavernosum, Ang-(1–7) increases NO production and facilitates penile erection and is considered a key component of the pro-erectile axis of the RAS. This chapter aims to summarize the current literature addressing the pathophysiological role of RAS in erectile function.

Keywords

Erectile Dysfunction Erectile Function Corpus Cavernosum Penile Erection Erectile Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ma TK et al (2010) Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 160(6):1273–1292PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Schiffrin EL (2002) Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 113(5):409–418PubMedCrossRefGoogle Scholar
  3. 3.
    Bader M (2010) Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Annu Rev Pharmacol Toxicol 50:439–465PubMedCrossRefGoogle Scholar
  4. 4.
    Dzau VJ (1988) Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 77(6 Pt 2):I4–I13PubMedGoogle Scholar
  5. 5.
    Dostal DE, Baker KM (1999) The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 85(7):643–650PubMedCrossRefGoogle Scholar
  6. 6.
    Paul M, Poyan Mehr A, Kreutz R (2006) Physiology of local renin-angiotensin systems. Physiol Rev 86(3):747–803PubMedCrossRefGoogle Scholar
  7. 7.
    Bader M, Ganten D (2008) Update on tissue renin-angiotensin systems. J Mol Med (Berl) 86(6):615–621CrossRefGoogle Scholar
  8. 8.
    Fraga-Silva RA et al (2013) Pathophysiological role of the renin-angiotensin system on erectile dysfunction. Eur J Clin Invest 43(9):978–985PubMedCrossRefGoogle Scholar
  9. 9.
    Becker AJ et al (2001) Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence. Urology 57(1):193–198PubMedCrossRefGoogle Scholar
  10. 10.
    Becker AJ et al (2001) Plasma levels of angiotensin II during different penile conditions in the cavernous and systemic blood of healthy men and patients with erectile dysfunction. Urology 58(5):805–810PubMedCrossRefGoogle Scholar
  11. 11.
    Ferreira AJ et al (2010) Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension 55(2):207–213PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Fraga-Silva RA, Ferreira AJ, Dos Santos RA (2013) Opportunities for targeting the angiotensin-converting enzyme 2/angiotensin-(1–7)/mas receptor pathway in hypertension. Curr Hypertens Rep 15(1):31–38PubMedCrossRefGoogle Scholar
  13. 13.
    da Costa Goncalves AC et al (2007) Evidence that the vasodilator angiotensin-(1–7)-Mas axis plays an important role in erectile function. Am J Physiol Heart Circ Physiol 293(4):H2588–H2596PubMedCrossRefGoogle Scholar
  14. 14.
    Kokubu T et al (1979) Purification and properties of angiotensin I-converting enzyme in human lung and its role on the metabolism of vasoactive peptides in pulmonary circulation. Adv Exp Med Biol 120B:467–475PubMedGoogle Scholar
  15. 15.
    Unger T (2002) The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 89(2A):3A–9A; discussion 10APubMedCrossRefGoogle Scholar
  16. 16.
    Levy BI (2005) How to explain the differences between renin angiotensin system modulators. Am J Hypertens 18(9 Pt 2):134S–141SPubMedCrossRefGoogle Scholar
  17. 17.
    Widdop RE et al (2002) AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension 40(4):516–520PubMedCrossRefGoogle Scholar
  18. 18.
    Savoia C et al (2011) Angiotensin type 2 receptor in hypertensive cardiovascular disease. Curr Opin Nephrol Hypertens 20(2):125–132PubMedCrossRefGoogle Scholar
  19. 19.
    Steckelings UM et al (2011) Non-peptide AT2-receptor agonists. Curr Opin Pharmacol 11(2):187–192PubMedCrossRefGoogle Scholar
  20. 20.
    Vickers C et al (2002) Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277(17):14838–14843PubMedCrossRefGoogle Scholar
  21. 21.
    Zisman LS et al (2003) Angiotensin-(1–7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate. Circulation 108(14):1679–1681PubMedCrossRefGoogle Scholar
  22. 22.
    Ferrario CM et al (1997) Counterregulatory actions of angiotensin-(1–7). Hypertension 30(3 Pt 2):535–541PubMedCrossRefGoogle Scholar
  23. 23.
    Santos RA et al (2003) Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100(14):8258–8263PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Sampaio WO et al (2007) Angiotensin-(1–7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 49(1):185–192PubMedCrossRefGoogle Scholar
  25. 25.
    Langeveld B et al (2005) Angiotensin-(1–7) attenuates neointimal formation after stent implantation in the rat. Hypertension 45(1):138–141PubMedCrossRefGoogle Scholar
  26. 26.
    Katovich MJ, Grobe JL, Raizada MK (2008) Angiotensin-(1–7) as an antihypertensive, antifibrotic target. Curr Hypertens Rep 10(3):227–232PubMedCrossRefGoogle Scholar
  27. 27.
    da Silveira KD et al (2010) Anti-inflammatory effects of the activation of the angiotensin-(1–7) receptor, MAS, in experimental models of arthritis. J Immunol 185(9):5569–5576PubMedCrossRefGoogle Scholar
  28. 28.
    Rice GI et al (2004) Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 383(Pt 1):45–51PubMedCentralPubMedGoogle Scholar
  29. 29.
    Stanziola L, Greene LJ, Santos RA (1999) Effect of chronic angiotensin converting enzyme inhibition on angiotensin I and bradykinin metabolism in rats. Am J Hypertens 12(10 Pt 1):1021–1029PubMedCrossRefGoogle Scholar
  30. 30.
    Park JK et al (1997) Renin angiotensin system in rabbit corpus cavernosum: functional characterization of angiotensin II receptors. J Urol 158(2):653–658PubMedCrossRefGoogle Scholar
  31. 31.
    Jin LM (2009) Angiotensin II signaling and its implication in erectile dysfunction. J Sex Med 6(Suppl 3):302–310PubMedCrossRefGoogle Scholar
  32. 32.
    Kifor I et al (1997) Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 157(5):1920–1925PubMedCrossRefGoogle Scholar
  33. 33.
    Iwamoto Y et al (2001) Multiple pathways of angiotensin I conversion and their functional role in the canine penile corpus cavernosum. J Pharmacol Exp Ther 298(1):43–48PubMedGoogle Scholar
  34. 34.
    Touyz RM, Berry C (2002) Recent advances in angiotensin II signaling. Braz J Med Biol Res 35(9):1001–1015PubMedCrossRefGoogle Scholar
  35. 35.
    Wynne BM, Chiao CW, Webb RC (2009) Vascular smooth muscle cell signaling mechanisms for contraction to angiotensin II and endothelin-1. J Am Soc Hypertens 3(2):84–95PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Ying Z et al (2006) Angiotensin II up-regulates the leukemia-associated Rho guanine nucleotide exchange factor (RhoGEF), a regulator of G protein signaling domain-containing RhoGEF, in vascular smooth muscle cells. Mol Pharmacol 69(3):932–940PubMedGoogle Scholar
  37. 37.
    Bivalacqua TJ et al (2003) Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease. J Androl 24(6 Suppl):S17–S37PubMedGoogle Scholar
  38. 38.
    Jin L et al (2008) NADPH oxidase activation: a mechanism of hypertension-associated erectile dysfunction. J Sex Med 5(3):544–551PubMedCrossRefGoogle Scholar
  39. 39.
    Horiuchi M, Iwanami J, Mogi M (2012) Regulation of angiotensin II receptors beyond the classical pathway. Clin Sci (Lond) 123(4):193–203CrossRefGoogle Scholar
  40. 40.
    Nguyen Dinh Cat A, Touyz RM (2011) Cell signaling of angiotensin II on vascular tone: novel mechanisms. Curr Hypertens Rep 13(2):122–128PubMedCrossRefGoogle Scholar
  41. 41.
    Unger T (1999) The angiotensin type 2 receptor: variations on an enigmatic theme. J Hypertens 17(12 Pt 2):1775–1786PubMedCrossRefGoogle Scholar
  42. 42.
    Lin CS et al (2001) Gene expression profiling of an arteriogenic impotence model. Biochem Biophys Res Commun 285(2):565–569PubMedCrossRefGoogle Scholar
  43. 43.
    Yousif MH, Kehinde EO, Benter IF (2007) Different responses to angiotensin-(1–7) in young, aged and diabetic rabbit corpus cavernosum. Pharmacol Res 56(3):209–216PubMedCrossRefGoogle Scholar
  44. 44.
    Li SX, Dai YT (2005) Effects of angiotensin II on male rats with diabetic erectile dysfunction. Zhonghua Nan Ke Xue 11(5):346–349PubMedGoogle Scholar
  45. 45.
    Chen Y et al (2012) Losartan improves erectile dysfunction in diabetic patients: a clinical trial. Int J Impot Res 24(6):217–220PubMedCrossRefGoogle Scholar
  46. 46.
    Dorrance AM, Lewis RW, Mills TM (2002) Captopril treatment reverses erectile dysfunction in male stroke prone spontaneously hypertensive rats. Int J Impot Res 14(6):494–497PubMedCrossRefGoogle Scholar
  47. 47.
    Yang R et al (2009) Losartan, an Angiotensin type I receptor, restores erectile function by downregulation of cavernous renin-angiotensin system in streptozocin-induced diabetic rats. J Sex Med 6(3):696–707PubMedCrossRefGoogle Scholar
  48. 48.
    Schlimmer N et al (2011) Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis. Br J Pharmacol 163(4):804–814PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Kloner RA et al (2003) Erectile dysfunction in the cardiac patient: how common and should we treat? J Urol 170(2 Pt 2):S46–S50; discussion S50PubMedCrossRefGoogle Scholar
  50. 50.
    Fogari R et al (2001) Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 14(1):27–31PubMedCrossRefGoogle Scholar
  51. 51.
    Llisterri JL et al (2001) Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 321(5):336–341PubMedCrossRefGoogle Scholar
  52. 52.
    Della Chiesa A et al (2003) Sexual activity in hypertensive men. J Hum Hypertens 17(8):515–521PubMedCrossRefGoogle Scholar
  53. 53.
    Dusing R (2005) Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs 65(6):773–786PubMedCrossRefGoogle Scholar
  54. 54.
    Suzuki H et al (1988) Effects of first-line antihypertensive agents on sexual function and sex hormones. J Hypertens Suppl 6(4):S649–S651PubMedCrossRefGoogle Scholar
  55. 55.
    Fogari R et al (1998) Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Am J Hypertens 11(10):1244–1247PubMedCrossRefGoogle Scholar
  56. 56.
    Segal RL, Bivalacqua TJ, Burnett AL (2012) Irbesartan promotes erection recovery after nerve-sparing radical retropubic prostatectomy: a retrospective long-term analysis. BJU Int 110(11):1782–1786PubMedCrossRefGoogle Scholar
  57. 57.
    Ekman E et al (2010) Antihypertensive drugs and erectile dysfunction as seen in spontaneous reports, with focus on angiotensin II type 1 receptor blockers. Drug Healthc Patient Saf 2:21–25PubMedCentralPubMedCrossRefGoogle Scholar
  58. 58.
    Fraga-Silva RA et al (2013) An oral formulation of angiotensin-(1–7) reverses corpus cavernosum damages induced by hypercholesterolemia. J Sex Med 10(10):2430–2442PubMedGoogle Scholar
  59. 59.
    Kilarkaje N et al (2013) Role of angiotensin II and angiotensin-(1–7) in diabetes-induced oxidative DNA damage in the corpus cavernosum. Fertil Steril 100(1):226–233PubMedCrossRefGoogle Scholar
  60. 60.
    da Costa Goncalves AC et al (2013) AVE 0991, a non-peptide Mas-receptor agonist, facilitates penile erection. Exp Physiol 98(3):850–855PubMedCrossRefGoogle Scholar
  61. 61.
    Shenoy V et al (2010) The angiotensin-converting enzyme 2/angiogenesis-(1–7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 182(8):1065–1072PubMedCentralPubMedCrossRefGoogle Scholar
  62. 62.
    Pei Z et al (2010) Angiotensin-(1–7) ameliorates myocardial remodeling and interstitial fibrosis in spontaneous hypertension: role of MMPs/TIMPs. Toxicol Lett 199(2):173–181PubMedCrossRefGoogle Scholar
  63. 63.
    Ferreira AJ et al (2011) Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 96(3):287–294PubMedCentralPubMedCrossRefGoogle Scholar
  64. 64.
    McCollum LT, Gallagher PE, Ann Tallant E (2012) Angiotensin-(1–7) attenuates angiotensin II-induced cardiac remodeling associated with upregulation of dual-specificity phosphatase 1. Am J Physiol Heart Circ Physiol 302(3):H801–H810PubMedCentralPubMedCrossRefGoogle Scholar
  65. 65.
    Lula I et al (2007) Study of angiotensin-(1–7) vasoactive peptide and its beta-cyclodextrin inclusion complexes: complete sequence-specific NMR assignments and structural studies. Peptides 28(11):2199–2210PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Rodrigo Araujo Fraga-Silva
    • 1
    Email author
  • Nikolaos Stergiopulos
    • 1
  1. 1.Institute of BioengineeringEcole Polytechnique Fédérale de LausanneLausanneSwitzerland

Personalised recommendations